D3-creatine dilution, computed tomography and dual-energy X-ray absorptiometry for assessing myopenia and physical function in colon cancer: A cross-sectional study.
Computed tomography
D3-Creatine
Dual-energy X-ray absorptiometry
Muscle
Physical performance
Sex
X-ray
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
30 Oct 2023
30 Oct 2023
Historique:
revised:
23
08
2023
received:
20
10
2022
accepted:
11
09
2023
medline:
30
10
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
aheadofprint
Résumé
Low skeletal muscle mass (myopenia) is common in cancer populations and is associated with functional decline and mortality, but prior oncology studies did not assess total body skeletal muscle mass. Instead, they measured surrogates such as cross-sectional area (CSA) of skeletal muscle at L3 from computed tomography (CT) or appendicular lean mass (ALM) from dual-energy X-ray absorptiometry (DXA). D3-creatine (D3Cr) dilution is a non-invasive method to assess total body skeletal muscle mass, which has been examined in a variety of populations but not in cancer. To compare the associations of D3Cr muscle mass, CT CSA, and DXA ALM with myopenia and physical function, we conducted a cross-sectional study among 119 patients with colon cancer (2018-2022). For each technique (D3Cr, CT and DXA), myopenia was defined as the lowest sex-specific quartile of its measurement. Physical function was measured by the short physical performance battery and grip strength. We calculated Pearson correlations (r) among three techniques, computed Cohen's kappa coefficients (κ) to assess the agreement of myopenia, and estimated Pearson correlations (r) of three techniques with physical function. All analyses were sex-specific. Sixty-one (51.3%) participants were male, the mean (standard deviation) age was 56.6 (12.9) years, and most (68.9%) had high physical function (short physical performance battery: ≥11 points). Correlations and myopenia agreement among three techniques were greater in men than women; for example, regarding D3Cr muscle mass versus CT CSA, r was 0.73 (P < 0.001) for men versus 0.45 (P < 0.001) for women, and κ was 0.82 (95% CI: 0.65, 0.99) for men versus 0.24 (95% CI: -0.08, 0.52) for women. Among men, higher D3Cr muscle mass was significantly correlated with faster gait speed (r = 0.43, P < 0.01) and stronger grip strength (r = 0.32, P < 0.05); similar correlations were observed for CT CSA and DXA ALM. However, among women, no measure of muscle or lean mass was significantly associated with physical function. This is the first study using D3-creatine dilution method to assess muscle mass in a cancer population. Regardless of the techniques used for muscle or lean mass assessment, we observed stronger correlations, greater myopenia agreement, and more significant associations with physical function in men with colon cancer than women. D3Cr, CT and DXA are not interchangeable methods for assessing myopenia and physical function, especially in women with colon cancer. Future studies should consider relative advantages of these techniques and examine the D3-creatine dilution method in other cancer types.
Sections du résumé
BACKGROUND
BACKGROUND
Low skeletal muscle mass (myopenia) is common in cancer populations and is associated with functional decline and mortality, but prior oncology studies did not assess total body skeletal muscle mass. Instead, they measured surrogates such as cross-sectional area (CSA) of skeletal muscle at L3 from computed tomography (CT) or appendicular lean mass (ALM) from dual-energy X-ray absorptiometry (DXA). D3-creatine (D3Cr) dilution is a non-invasive method to assess total body skeletal muscle mass, which has been examined in a variety of populations but not in cancer. To compare the associations of D3Cr muscle mass, CT CSA, and DXA ALM with myopenia and physical function, we conducted a cross-sectional study among 119 patients with colon cancer (2018-2022).
METHODS
METHODS
For each technique (D3Cr, CT and DXA), myopenia was defined as the lowest sex-specific quartile of its measurement. Physical function was measured by the short physical performance battery and grip strength. We calculated Pearson correlations (r) among three techniques, computed Cohen's kappa coefficients (κ) to assess the agreement of myopenia, and estimated Pearson correlations (r) of three techniques with physical function. All analyses were sex-specific.
RESULTS
RESULTS
Sixty-one (51.3%) participants were male, the mean (standard deviation) age was 56.6 (12.9) years, and most (68.9%) had high physical function (short physical performance battery: ≥11 points). Correlations and myopenia agreement among three techniques were greater in men than women; for example, regarding D3Cr muscle mass versus CT CSA, r was 0.73 (P < 0.001) for men versus 0.45 (P < 0.001) for women, and κ was 0.82 (95% CI: 0.65, 0.99) for men versus 0.24 (95% CI: -0.08, 0.52) for women. Among men, higher D3Cr muscle mass was significantly correlated with faster gait speed (r = 0.43, P < 0.01) and stronger grip strength (r = 0.32, P < 0.05); similar correlations were observed for CT CSA and DXA ALM. However, among women, no measure of muscle or lean mass was significantly associated with physical function.
CONCLUSIONS
CONCLUSIONS
This is the first study using D3-creatine dilution method to assess muscle mass in a cancer population. Regardless of the techniques used for muscle or lean mass assessment, we observed stronger correlations, greater myopenia agreement, and more significant associations with physical function in men with colon cancer than women. D3Cr, CT and DXA are not interchangeable methods for assessing myopenia and physical function, especially in women with colon cancer. Future studies should consider relative advantages of these techniques and examine the D3-creatine dilution method in other cancer types.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Cancer Institute of the National Institutes of Health
ID : R37CA263064
Organisme : National Cancer Institute of the National Institutes of Health
ID : R01CA206196
Organisme : National Cancer Institute of the National Institutes of Health
ID : R01CA240394
Informations de copyright
© 2023 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.
Références
Johns N, Stephens NA, Fearon KC. Muscle wasting in cancer. Int J Biochem Cell Biol 2013;45:2215-2229.
Cespedes Feliciano EM, Lee VS, Prado CM, Meyerhardt JA, Alexeeff S, Kroenke CH, et al. Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study. Cancer 2017;123:4868-4877.
Cheng E, Caan B, Cawthon P, Evans WJ, Hellerstein MK, Shankaran M, et al. Body composition, relative dose intensity, and adverse events among patients with colon cancer. Cancer Epidemiol Biomarkers Prev 2023;1538-7755) (Electronic) (In eng), https://doi.org/10.1158/1055-9965.EPI-23-0227
Xiao J, Caan BJ, Cespedes Feliciano EM, Meyerhardt JA, Peng PD, Baracos VE, et al. Association of low muscle mass and low muscle radiodensity with morbidity and mortality for colon cancer surgery. JAMA Surg 2020;155:942-949.
Caan BJ, Meyerhardt JA, Kroenke CH, Alexeeff S, Xiao J, Weltzien E, et al. Explaining the obesity paradox: the association between body composition and colorectal cancer survival (C-SCANS study). Cancer Epidemiol Biomarkers Prev 2017;26:1008-1015.
Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr 2017;36:1187-1196.
Barazzoni R, Jensen GL, Correia M, Gonzalez MC, Higashiguchi T, Shi HP, et al. Guidance for assessment of the muscle mass phenotypic criterion for the global leadership initiative on malnutrition (GLIM) diagnosis of malnutrition. Clin Nutr 2022;41:1425-1433.
Clark RV, Walker AC, O'Connor-Semmes RL, Leonard MS, Miller RR, Stimpson SA, et al. Total body skeletal muscle mass: estimation by creatine (methyl-d3) dilution in humans. J Appl Physiol 1985;116:1605-1613.
Clark RV, Walker AC, Miller RR, O'Connor-Semmes RL, Ravussin E, Cefalu WT. Creatine (methyl-d3) dilution in urine for estimation of total body skeletal muscle mass: accuracy and variability vs. MRI and DXA. J Appl Physiol 1985;124:1-9.
Cawthon PM, Orwoll ES, Peters KE, Ensrud KE, Cauley JA, Kado DM, et al. Strong relation between muscle mass determined by D3-creatine dilution, physical performance, and incidence of falls and mobility limitations in a prospective cohort of older men. J Gerontol: Series A 2019;74:844-852.
Cawthon PM, Blackwell T, Cummings SR, Orwoll ES, Duchowny KA, Kado DM, et al. Muscle mass assessed by the D3-creatine dilution method and incident self-reported disability and mortality in a prospective observational study of community-dwelling older men. J Gerontol A Biol Sci Med Sci 2021;76:123-130.
Zhu K, Wactawski-Wende J, Ochs-Balcom HM, LaMonte MJ, Hovey KM, Evans W, et al. The association of muscle mass measured by D3-creatine dilution method with dual-energy X-ray absorptiometry and physical function in postmenopausal women. J Gerontol: Series A 2021;76:1591-1599.
McCarthy C, Schoeller D, Brown JC, Gonzalez MC, Varanoske AN, Cataldi D, et al. D(3) -creatine dilution for skeletal muscle mass measurement: historical development and current status. J Cachexia Sarcopenia Muscle 2022;13:2595-2607.
Shankaran M, Czerwieniec G, Fessler C, Wong PYA, Killion S, Turner SM, et al. Dilution of oral D3-creatine to measure creatine pool size and estimate skeletal muscle mass: development of a correction algorithm. J Cachexia Sarcopenia Muscle 2018;9:540-546.
Buckinx F, Landi F, Cesari M, Fielding RA, Visser M, Engelke K, et al. Pitfalls in the measurement of muscle mass: a need for a reference standard. J Cachexia Sarcopenia Muscle 2018;9:269-278.
Anderson LJ, Liu H, Garcia JM. Sex differences in muscle wasting. In Mauvais-Jarvis F, ed. Sex and gender factors affecting metabolic homeostasis, diabetes and obesity. Cham, Switzerland: Springer International Publishing; 2017. p 153-197.
Caan BJ, Meyerhardt JA, Brown JC, Campbell KL, Cespedes Feliciano EM, Lee C, et al. Recruitment strategies and design considerations in a trial of resistance training to prevent dose-limiting toxicities in colon cancer patients undergoing chemotherapy. Contemp Clin Trials 2021;101:106242.
Leonard M, Dunn J, Smith G. A clinical biomarker assay for the quantification of D3-creatinine and creatinine using LC-MS/MS. Bioanalysis 2014;6:745-759.
Shen W, Punyanitya M, Wang Z, Gallagher D, St.-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 1985;97:2333-2338.
Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994;49:M85-M94.
Mijnarends DM, Meijers JM, Halfens RJ, ter Borg S, Luiking YC, Verlaan S, et al. Validity and reliability of tools to measure muscle mass, strength, and physical performance in community-dwelling older people: a systematic review. J Am Med Dir Assoc 2013;14:170-178.
Pearson K. Note on regression and inheritance in the case of two parents. Proc R Soc Lond 1895;58:240-242.
Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37-46.
Zar JH. Biostatistical Analysis, 5th ed. Upper Saddle River, NJ: Pearson Education. Inc.; 2010.
Guilford JP. Fundamental statistics in psychology and education. New York, NY: McGraw-Hill; 1973.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174.
Mazess RB, Barden HS, Bisek JP, Hanson J. Dual-energy X-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr 1990;51:1106-1112.
Evans WJ, Scottoline B, Imam F, Hellerstein M, Garton K, Czerwieniec G, et al. D3-creatine dilution for the noninvasive measurement of skeletal muscle mass in premature infants. Pediatr Res 2021;89:1508-1514.
Evans WJ, Shankaran M, Smith EC, Morris C, Nyangau E, Bizieff A, et al. Profoundly lower muscle mass and rate of contractile protein synthesis in boys with Duchenne muscular dystrophy. J Physiol 2021;599:5215-5227.
Janssen I, Heymsfield SB, Wang Z, Ross R. Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. J Appl Physiol 2000;89:81-88.
Montalvo RN, Counts BR, Carson JA. Understanding sex differences in the regulation of cancer-induced muscle wasting. Curr Opin Support Palliat Care 2018;12:394-403.
Zhong X, Zimmers TA. Sex differences in cancer cachexia. Curr Osteoporos Rep 2020;18:646-654.
Bland JM, Altman DG. Correlation in restricted ranges of data. BMJ 2011;342:d556.
Orwoll ES, Blackwell T, Cummings SR, Cauley JA, Lane NE, Hoffman AR, et al. CT muscle density, D3Cr muscle mass, and body fat associations with physical performance, mobility outcomes, and mortality risk in older men. J Gerontol A Biol Sci Med Sci 2022;77:790-799.
Brown JC, Harhay MO, Harhay MN. Physical function as a prognostic biomarker among cancer survivors. Br J Cancer 2015;112:194-198.
Barbalho ER, Gonzalez MC, Bielemann RM, da Rocha IMG, de Sousa IM, Bezerra RA, et al. Is skeletal muscle radiodensity able to indicate physical function impairment in older adults with gastrointestinal cancer? Exp Gerontol 2019;125:110688.
Prado CM, Lieffers JR, Bowthorpe L, Baracos VE, Mourtzakis M, McCargar LJ. Sarcopenia and physical function in overweight patients with advanced cancer. Can J Diet Pract Res 2013;74:69-74.
Stephens NA, Gray C, MacDonald AJ, Tan BH, Gallagher IJ, Skipworth RJ, et al. Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin Nutr 2012;31:499-505.
von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021. J Cachexia Sarcopenia Muscle 2021;12:2259-2261.